Overview

Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $3.15 + 0.04 (1.29%)
ExchangeNASDAQ GS
Volume47,036
Today's Open$3.14
Previous Close$3.11
Data as of 02/21/18 3:32 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $3.15 with a 52 week high of $7.93 and a 52 week low of $2.60.
Recent News

January 11, 2018

Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference

Download Presentation (PDF)To watch the WebcastTo Listen to the Webcast...

Read More >

January 05, 2018

Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA

Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks, the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr. Patrick Soon-Shiong (Chairman, CEO, and Founder) will present the current status of these companies and the overall ecosystem of NantWorks. Specific details will be presented regarding the current status of...

Read More >

December 04, 2017

NantHealth to Support the University of California San Francisco in Research Initiative Focused on Metastatic Breast Cancer

NantHealth will provide GPS Cancer molecular analysis to help UCSF better understand the molecular basis of metastatic breast cancer in order to develop personalized therapy for individual patients CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 4, 2017-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced its support for a research study initiated by the University of Califor...

Read More >

Upcoming Events
There are currently no events scheduled.